Harmony Biosciences’ Fragile X Trial Falls Short but Offers Key Insights
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported topline results from its Phase 3 RECONNECT study of ZYN002 in Fragile X syndrome (FXS), announcing that the trial …
Harmony Biosciences’ Fragile X Trial Falls Short but Offers Key Insights Read More